Forma takes aim at Agios with new AML complete remission data

Forma Therapeutics went public this year and raised $320 million in large part on the strength of their Phase I/II sickle cell program. But their non-core programs also held promise, including that they could go toe-to-toe with Agios on acute myeloid leukemia. Today, the Massachusetts biotech announced they’ve done that — almost to a tee.